Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Launches The Desire Project to Promote MDMA-Assisted Psychotherapy Treatment for HSDD
Although an often unspoken of medical disorder, Hypoactive Sexual Desire Disorder affects approximately 9.5 million women in the U.S. alone The project gathers some of the world’s leading researchers in female sexual desire and psychedelics This is the first-of-its-kind psychedelic-based treatment program targeting this disorder, with potential global implications Clinical trials of MDMA as a treatment for PTSD have shown some success due to targeting the pathways that process fear MINDCURE is working with a molecule that will be first-to-market - MDMA is predicted to be approved by 2023 – this brings them closer to the money Mind Cure Health…